Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Biersack

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Der Internist|September 25, 2013
[Delayed effects of oncological therapy]H Biersack, G Brabant
Acta Oncologica (Stockholm, Sweden)|January 1, 1994
Drug-sensitivity and DNA-binding of a subform of topoisomerase II alpha in resistant human HL-60 cellsF Boege, H Biersack, P Meyer
Leukemia & Lymphoma|March 1, 1993
Different functional states of topoisomerase II can be discriminated by orthovanadate sensitivity in multi-drug resistant human leukemic cellsF Boege, F Gieseler, H Biersack, et al.
Journal of Chromatography|November 29, 1991
Use of anion-exchange chromatography and chromatofocusing to reveal the structural and functional heterogeneity of topoisomerase II in a HL-60 cell line resistant to multi-drug treatmentF Boege, F Gieseler, H Biersack, et al.
European Journal of Clinical Chemistry and Clinical Biochemistry : Journal of the Forum of European Clinical Chemistry Societies|February 1, 1992
The measurement of nuclear topoisomerase II inhibition in vitro: a possible tool for detecting resistance on a subcellular level in haematopoietic malignanciesF Boege, F Gieseler, H Biersack, et al.
Journal of Chromatography|November 13, 1992
Activation of topoisomerase II during partial purification by heparin-Sepharose chromatographyF Boege, F Gieseler, M Müller, et al.
European Journal of Biochemistry|December 1, 1993
A drug-resistant variant of topoisomerase II alpha in human HL-60 cells exhibits alterations in catalytic pH optimum, DNA binding and sub-nuclear distributionF Boege, E Kjeldsen, F Gieseler, et al.
International Urology and Nephrology|January 1, 1987
The diagnostic significance of magnetic resonance imaging in prostatic tumoursN Jaeger, A Bockisch, B Hünermann, et al.
Annals of Hematology|January 1, 1994
Cytotoxicity of anthracyclines: correlation with cellular uptake, intracellular distribution and DNA bindingF Gieseler, H Biersack, T Brieden, et al.
Leukemia & Lymphoma|July 29, 2016
Nuclear Topoisomerase II Activity Changes During HL-60 Leukemic Cell Differentiation: Alterations in Drug Sensitivity and pH DependencyF Gieseler, F Boege, H Biersack, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Der Internist|September 25, 2013
[Delayed effects of oncological therapy]H Biersack, G Brabant
Acta Oncologica (Stockholm, Sweden)|January 1, 1994
Drug-sensitivity and DNA-binding of a subform of topoisomerase II alpha in resistant human HL-60 cellsF Boege, H Biersack, P Meyer
Leukemia & Lymphoma|March 1, 1993
Different functional states of topoisomerase II can be discriminated by orthovanadate sensitivity in multi-drug resistant human leukemic cellsF Boege, F Gieseler, H Biersack, et al.
Journal of Chromatography|November 29, 1991
Use of anion-exchange chromatography and chromatofocusing to reveal the structural and functional heterogeneity of topoisomerase II in a HL-60 cell line resistant to multi-drug treatmentF Boege, F Gieseler, H Biersack, et al.
European Journal of Clinical Chemistry and Clinical Biochemistry : Journal of the Forum of European Clinical Chemistry Societies|February 1, 1992
The measurement of nuclear topoisomerase II inhibition in vitro: a possible tool for detecting resistance on a subcellular level in haematopoietic malignanciesF Boege, F Gieseler, H Biersack, et al.
Journal of Chromatography|November 13, 1992
Activation of topoisomerase II during partial purification by heparin-Sepharose chromatographyF Boege, F Gieseler, M Müller, et al.
European Journal of Biochemistry|December 1, 1993
A drug-resistant variant of topoisomerase II alpha in human HL-60 cells exhibits alterations in catalytic pH optimum, DNA binding and sub-nuclear distributionF Boege, E Kjeldsen, F Gieseler, et al.
International Urology and Nephrology|January 1, 1987
The diagnostic significance of magnetic resonance imaging in prostatic tumoursN Jaeger, A Bockisch, B Hünermann, et al.
Annals of Hematology|January 1, 1994
Cytotoxicity of anthracyclines: correlation with cellular uptake, intracellular distribution and DNA bindingF Gieseler, H Biersack, T Brieden, et al.
Leukemia & Lymphoma|July 29, 2016
Nuclear Topoisomerase II Activity Changes During HL-60 Leukemic Cell Differentiation: Alterations in Drug Sensitivity and pH DependencyF Gieseler, F Boege, H Biersack, et al.
Pageof 2